JP6765090B2 - Black ginger-containing composition - Google Patents
Black ginger-containing composition Download PDFInfo
- Publication number
- JP6765090B2 JP6765090B2 JP2019091315A JP2019091315A JP6765090B2 JP 6765090 B2 JP6765090 B2 JP 6765090B2 JP 2019091315 A JP2019091315 A JP 2019091315A JP 2019091315 A JP2019091315 A JP 2019091315A JP 6765090 B2 JP6765090 B2 JP 6765090B2
- Authority
- JP
- Japan
- Prior art keywords
- mass
- black ginger
- parts
- composition
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 116
- 235000006886 Zingiber officinale Nutrition 0.000 title claims description 86
- 235000008397 ginger Nutrition 0.000 title claims description 86
- 241000234314 Zingiber Species 0.000 title claims description 85
- 230000001737 promoting effect Effects 0.000 claims description 51
- 239000004475 Arginine Substances 0.000 claims description 14
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 14
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 13
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 13
- 210000000577 adipose tissue Anatomy 0.000 claims description 12
- 230000003579 anti-obesity Effects 0.000 claims description 12
- 230000004060 metabolic process Effects 0.000 claims description 12
- 230000001603 reducing effect Effects 0.000 claims description 9
- 241000395050 Kaempferia parviflora Species 0.000 claims description 6
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 46
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 46
- 229940002508 ginger extract Drugs 0.000 description 46
- 235000020708 ginger extract Nutrition 0.000 description 46
- 239000000126 substance Substances 0.000 description 45
- 238000012360 testing method Methods 0.000 description 43
- 230000009471 action Effects 0.000 description 41
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 34
- 210000001593 brown adipocyte Anatomy 0.000 description 29
- 239000000284 extract Substances 0.000 description 29
- 229920001542 oligosaccharide Polymers 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 20
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 20
- 229960001948 caffeine Drugs 0.000 description 20
- 150000002482 oligosaccharides Chemical class 0.000 description 20
- 102000016942 Elastin Human genes 0.000 description 19
- 108010014258 Elastin Proteins 0.000 description 19
- 229940024606 amino acid Drugs 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 19
- 229920002549 elastin Polymers 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 244000025221 Humulus lupulus Species 0.000 description 17
- 235000008694 Humulus lupulus Nutrition 0.000 description 17
- 229940074391 gallic acid Drugs 0.000 description 17
- 235000004515 gallic acid Nutrition 0.000 description 17
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 14
- 229960003767 alanine Drugs 0.000 description 14
- 235000004279 alanine Nutrition 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 230000004069 differentiation Effects 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 229960003121 arginine Drugs 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 208000008589 Obesity Diseases 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 235000020824 obesity Nutrition 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 235000013399 edible fruits Nutrition 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 9
- 229940107187 fructooligosaccharide Drugs 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 230000001953 sensory effect Effects 0.000 description 9
- 235000019640 taste Nutrition 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 210000003486 adipose tissue brown Anatomy 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 240000000366 Melilotus officinalis Species 0.000 description 7
- 235000017822 Melilotus officinalis Nutrition 0.000 description 7
- 230000003213 activating effect Effects 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 241000218228 Humulus Species 0.000 description 6
- 206010022489 Insulin Resistance Diseases 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
- 210000001789 adipocyte Anatomy 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 229960001153 serine Drugs 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- 102000029816 Collagenase Human genes 0.000 description 5
- 108060005980 Collagenase Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 229960002424 collagenase Drugs 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000013922 glutamic acid Nutrition 0.000 description 5
- 239000004220 glutamic acid Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000008278 cosmetic cream Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- -1 milky Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- ALGDHWVALRSLBT-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxychromen-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 ALGDHWVALRSLBT-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- YZWIIEJLESXODL-UHFFFAOYSA-N 3,5,7-trimethoxy-2-(4-methoxyphenyl)chromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C=C(OC)C=C2O1 YZWIIEJLESXODL-UHFFFAOYSA-N 0.000 description 2
- 244000277285 Cassia obtusifolia Species 0.000 description 2
- 235000006719 Cassia obtusifolia Nutrition 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101150022052 UCP1 gene Proteins 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 235000014552 Cassia tora Nutrition 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000395033 Kaempferia Species 0.000 description 1
- 235000013422 Kaempferia rotunda Nutrition 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000027721 electron transport chain Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- KWXLCDNSEHTOCB-UHFFFAOYSA-J tetrasodium;1,1-diphosphonatoethanol Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P(=O)([O-])C(O)(C)P([O-])([O-])=O KWXLCDNSEHTOCB-UHFFFAOYSA-J 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 210000000636 white adipocyte Anatomy 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は、黒生姜及び特定の成分を含有し、かつ、ＵＣＰ１発現促進作用及び／又は褐色脂肪細胞分化促進作用を有する組成物に関する。 The present invention relates to a composition containing black ginger and a specific component, and having a UCP1 expression promoting action and / or a brown adipocyte differentiation promoting action.
脱共役タンパク質（Ｕｎｃｏｕｐｌｉｎｇ ｐｒｏｔｅｉｎｓ；ＵＣＰｓ）はミトコンドリア内膜での酸化的リン酸化反応を脱共役させ、エネルギーを熱として散逸する機能を有する（非特許文献１を参照）。特に、ＵＣＰ１は、熱産生部位である褐色脂肪細胞に特異的に発現し、電子伝達系におけるＡＴＰ合成を経ずに、中性脂質を熱へと変換し、直接的にエネルギーを消費させる役割を担う。また、前駆細胞からの褐色脂肪細胞への分化を促進することができれば、ＵＣＰ１の発現量を増大することができ、中性脂質を熱へと変換することが可能になる。したがって、ＵＣＰ１発現量又は褐色脂肪細胞分化を促進することができれば、中性脂質の消費を経て、肥満を解消できる可能性がある。このような、褐色脂肪細胞分化促進剤やＵＣＰ１発現促進剤について、カテキン類を有効成分とするものが特許文献１に記載がある。 Uncoupling proteins (UCPs) have the function of uncoupling the oxidative phosphorylation reaction in the inner mitochondrial membrane and dissipating energy as heat (see Non-Patent Document 1). In particular, UCP1 is specifically expressed in brown adipocytes, which are heat-producing sites, and has a role of converting neutral lipids into heat and directly consuming energy without going through ATP synthesis in the electron transport chain. Carry. In addition, if the differentiation of progenitor cells into brown adipocytes can be promoted, the expression level of UCP1 can be increased, and neutral lipids can be converted into heat. Therefore, if UCP1 expression level or brown adipocyte differentiation can be promoted, obesity may be eliminated through consumption of neutral lipids. Patent Document 1 describes such a brown adipocyte differentiation promoter and a UCP1 expression promoter containing catechins as an active ingredient.
特許文献１に記載のＵＣＰ１の発現量及び活性化を促進できるものは、天然物から単離及び精製した特定物質を有効成分として含有する。しかし、このような特定物質は、薬理作用が強いことから、摂取するに際して注意が必要であり、過剰な摂取により副作用がもたらされる危険性がある。 Those capable of promoting the expression level and activation of UCP1 described in Patent Document 1 contain a specific substance isolated and purified from a natural product as an active ingredient. However, since such a specific substance has a strong pharmacological action, care must be taken when ingesting it, and there is a risk of causing side effects due to excessive ingestion.
本発明は、このような事情に鑑みてなされたもので、副作用の問題がなく、長期的かつ持続的な摂取が可能である、ＵＣＰ１発現促進作用及び／又は褐色脂肪細胞分化促進作用を示す組成物を提供することを、発明が解決しようとする課題とする。 The present invention has been made in view of such circumstances, and has a composition exhibiting a UCP1 expression promoting action and / or a brown adipocyte differentiation promoting action, which has no problem of side effects and enables long-term and continuous ingestion. Providing goods is an issue that the invention seeks to solve.
本発明者らは、上記課題を解決するために鋭意検討したところ、驚くべきことに、黒生姜と特定の成分とを組み合わせることによって、相加的よりもむしろ相乗的にＵＣＰ１発現促進効果及び／又は褐色脂肪細胞分化促進効果が得られることを見出した。そして、ＵＣＰ１発現促進用組成物、代謝促進用組成物、抗肥満用組成物、体脂肪減少用組成物及び熱産生促進用組成物として、黒生姜と特定の成分とを含有する組成物の創作に成功した。本発明は、かかる知見や成功例に基づいて完成された発明である。 As a result of diligent studies to solve the above problems, the present inventors surprisingly found that the combination of black ginger and a specific component synergistically promotes UCP1 expression and / / Alternatively, it was found that an effect of promoting brown adipocyte differentiation can be obtained. Then, as a composition for promoting UCP1 expression, a composition for promoting metabolism, a composition for anti-obesity, a composition for reducing body fat, and a composition for promoting heat production, creation of a composition containing black ginger and a specific component. succeeded in. The present invention is an invention completed based on such findings and successful examples.
したがって、本発明によれば、黒生姜（Ｋａｅｍｐｆｅｒｉａ ｐａｒｖｉｆｌｏｒａ）と、ホップ、ケツメイシ、メリロート、ショウガ、エラスチン、没食子酸、カフェイン、オリゴ糖及びアミノ酸からなる群から選ばれる少なくとも１種類の成分とを含有する化粧用組成物が提供される。 Therefore, according to the present invention, it contains black ginger (Kaempferia parviflora) and at least one component selected from the group consisting of hops, ketsumeishi, melilote, ginger, elastin, gallic acid, caffeine, oligosaccharides and amino acids. Cosmetic compositions to be provided.
黒生姜と、ホップ、ケツメイシ、メリロート、ショウガ、エラスチン、没食子酸、カフェイン、オリゴ糖及びアミノ酸からなる群から選ばれる少なくとも１種類の成分とを含有するＵＣＰ１発現促進用組成物が提供される。 A UCP1 expression-promoting composition containing black ginger and at least one component selected from the group consisting of hops, ketsumeishi, melilote, ginger, elastin, gallic acid, caffeine, oligosaccharides and amino acids is provided.
本発明の別の側面によれば、黒生姜と、ホップ、ケツメイシ、メリロート、ショウガ、エラスチン、没食子酸、カフェイン、オリゴ糖及びアミノ酸からなる群から選ばれる少なくとも１種類の成分とを含有する褐色脂肪細胞活性化用組成物が提供される。 According to another aspect of the invention, brown containing black ginger and at least one component selected from the group consisting of hops, ketsumeishi, melilote, ginger, elastin, gallic acid, caffeine, oligosaccharides and amino acids. A composition for activating adipocytes is provided.
本発明の別の側面によれば、黒生姜と、ホップ、ケツメイシ、メリロート、ショウガ、エラスチン、没食子酸、カフェイン、オリゴ糖及びアミノ酸からなる群から選ばれる少なくとも１種類の成分とを含有する代謝促進用組成物が提供される。 According to another aspect of the invention, metabolism containing black ginger and at least one component selected from the group consisting of hops, ketsumeishi, melilote, ginger, elastin, gallic acid, caffeine, oligosaccharides and amino acids. Acceleration compositions are provided.
本発明の別の側面によれば、黒生姜と、ホップ、ケツメイシ、メリロート、ショウガ、エラスチン、没食子酸、カフェイン、オリゴ糖及びアミノ酸からなる群から選ばれる少なくとも１種類の成分とを含有する抗肥満用組成物が提供される。 According to another aspect of the invention, an anti-antibiate containing black ginger and at least one component selected from the group consisting of hops, ketsumeishi, melilote, ginger, elastin, gallic acid, caffeine, oligosaccharides and amino acids. Compositions for obesity are provided.
本発明の別の側面によれば、黒生姜と、ホップ、ケツメイシ、メリロート、ショウガ、エラスチン、没食子酸、カフェイン、オリゴ糖及びアミノ酸からなる群から選ばれる少なくとも１種類の成分とを含有する体脂肪減少用組成物が提供される。 According to another aspect of the invention, a body containing black ginger and at least one component selected from the group consisting of hops, ketsumeishi, melilote, ginger, elastin, gallic acid, caffeine, oligosaccharides and amino acids. A composition for reducing fat is provided.
本発明の別の側面によれば、黒生姜と、ホップ、ケツメイシ、メリロート、ショウガ、エラスチン、没食子酸、カフェイン、オリゴ糖及びアミノ酸からなる群から選ばれる少なくとも１種類の成分とを含有する熱産生促進用組成物が提供される。 According to another aspect of the invention, heat containing black ginger and at least one component selected from the group consisting of hops, ketsumeishi, melilote, ginger, elastin, gallic acid, caffeine, oligosaccharides and amino acids. A composition for promoting production is provided.
本発明の別の側面によれば、黒生姜と、ホップ、ケツメイシ、メリロート、ショウガ、エラスチン、没食子酸、カフェイン、オリゴ糖及びアミノ酸からなる群から選ばれる少なくとも１種類の成分とを含有する組成物が提供される。 According to another aspect of the present invention, a composition containing black ginger and at least one component selected from the group consisting of hops, ketsumeishi, melilote, ginger, elastin, gallic acid, caffeine, oligosaccharides and amino acids. Things are provided.
好ましくは、本発明の組成物は、褐色脂肪細胞活性化作用、代謝促進作用、抗肥満作用、体脂肪減少作用、熱産生促進作用、ＵＣＰ１発現促進作用、エネルギー産生促進作用、中性脂質低下作用、皮脂抑制作用及び脂肪代謝促進作用からなる群から選ばれる少なくとも１種類の作用を有する。 Preferably, the composition of the present invention has a brown adipocyte activating effect, a metabolism promoting effect, an anti-obesity effect, a body fat reducing effect, a thermogenin promoting effect, a UCP1 expression promoting effect, an energy production promoting effect, and a neutral lipid lowering effect. It has at least one action selected from the group consisting of a sebum-suppressing action and an adipocyte metabolism-promoting action.
好ましくは、本発明の組成物において、前記オリゴ糖は、イソマルトオリゴ糖、フラクトオリゴ糖及び乳果オリゴ糖からなる群から選ばれる少なくとも１種類のオリゴ糖である。 Preferably, in the composition of the present invention, the oligosaccharide is at least one oligosaccharide selected from the group consisting of isomaltooligosaccharides, fructooligosaccharides and milk fruit oligosaccharides.
好ましくは、本発明の組成物において、前記アミノ酸は、アラニン、アルギニン及びセリンからなる群から選ばれる少なくとも１種類のアミノ酸である。 Preferably, in the composition of the present invention, the amino acid is at least one amino acid selected from the group consisting of alanine, arginine and serine.
本発明の組成物は、ＵＣＰ１発現促進作用及び／又は褐色脂肪細胞分化促進作用を有し、さらにこれらの作用に関連して、褐色脂肪細胞活性化作用、代謝促進作用、抗肥満作用、体脂肪減少作用、熱産生促進作用、ＵＣＰ１発現促進作用、エネルギー産生促進作用、中性脂質低下作用、皮脂抑制作用、脂肪代謝促進作用などを示すことが期待できる。 The composition of the present invention has a UCP1 expression promoting action and / or a brown adipose cell differentiation promoting action, and in connection with these actions, a brown fat cell activating action, a metabolism promoting action, an anti-obesity action, and a body fat. It can be expected to exhibit a reducing action, a thermogenin promoting action, a UCP1 expression promoting action, an energy production promoting action, a neutral lipid lowering action, a sebum suppressing action, a fat metabolism promoting action and the like.
本発明の組成物で用いられる黒生姜及び特定の成分は、それぞれ医薬品や化粧品などでの使用実績のあるものであることから、本発明の組成物は安全性が高いものである。そこで、本発明の組成物は、上記作用を有することにより、ＵＣＰ１発現促進用組成物、代謝促進用組成物、抗肥満用組成物、体脂肪減少用組成物及び熱産生促進用組成物として有用であり、非経口的又は経口的な形態で提供することが期待できる。 Since the black ginger and the specific ingredient used in the composition of the present invention have been used in pharmaceuticals and cosmetics, respectively, the composition of the present invention is highly safe. Therefore, the composition of the present invention is useful as a composition for promoting UCP1 expression, a composition for promoting metabolism, a composition for anti-obesity, a composition for reducing body fat, and a composition for promoting heat production by having the above-mentioned actions. It can be expected to be provided in a parenteral or oral form.
以下、本発明について詳細に説明する。
本発明の組成物は、ＵＣＰ１発現促進作用及び／又は褐色脂肪細胞分化促進作用を有し、かつ、黒生姜（Ｋａｅｍｐｆｅｒｉａ ｐａｒｖｉｆｌｏｒａ）と、ホップ、ケツメイシ、メリロート、ショウガ、エラスチン、没食子酸、カフェイン、オリゴ糖及びアミノ酸のいずれかの成分（以下、特定成分とよぶ。）とを少なくとも含有する。
Hereinafter, the present invention will be described in detail.
The composition of the present invention has a UCP1 expression-promoting action and / or a brown adipose cell differentiation-promoting action, and contains black ginger ( Kaempferia parviflora ), hops, ketsumeishi, melilote, ginger, elastin, gallic acid, caffeine, and the like. It contains at least one of oligosaccharides and amino acids (hereinafter referred to as a specific component).
本発明の組成物は、ＵＣＰ１発現促進作用及び褐色脂肪細胞分化促進作用のうち、いずれか１種の作用を有するものであってもよいし、これら２種全ての作用を有するものであってもよい。また、黒生姜と組み合わせられる特定成分は、特定成分のうちのいずれか１種の成分であってもよいし、２種以上の成分であってもよい。例えば、特定成分のうちの、カフェイン、アラニン及びイソマルトオリゴ糖というような組み合わせが可能である。 The composition of the present invention may have any one of the UCP1 expression promoting action and the brown adipocyte differentiation promoting action, or may have all these two actions. Good. In addition, the specific component to be combined with black ginger may be any one of the specific components, or may be two or more components. For example, a combination of specific components such as caffeine, alanine and isomaltooligosaccharide is possible.
本発明の組成物は、ＵＣＰ１発現促進作用及び褐色脂肪細胞分化促進作用の他に、褐色脂肪細胞活性化作用、代謝促進作用、抗肥満作用、体脂肪減少作用、熱産生促進作用、エネルギー産生促進作用、中性脂質低下作用、皮脂抑制作用及び脂肪代謝促進作用を示し得る。 In addition to the UCP1 expression promoting action and the brown fat cell differentiation promoting action, the composition of the present invention has a brown fat cell activating action, a metabolism promoting action, an anti-obesity action, a body fat reducing action, a thermogenin promoting action, and an energy production promoting action. It can exhibit action, neutral lipid lowering action, sebum suppressing action and fat metabolism promoting action.
本発明の組成物は、上記した作用を有することにより、ＵＣＰ１発現促進用組成物、代謝促進用組成物、抗肥満用組成物、体脂肪減少用組成物及び熱産生促進用組成物という態様を採り得る。 By having the above-mentioned actions, the composition of the present invention comprises the aspects of a UCP1 expression promoting composition, a metabolism promoting composition, an anti-obesity composition, a body fat reducing composition and a thermogenin promoting composition. Can be taken.
黒生姜（Ｋａｅｍｐｆｅｒｉａ ｐａｒｖｉｆｌｏｒａ）は、東南アジアなどに自生することで知られているショウガ科バンウコン属の植物である。黒生姜は、精力増進、滋養強壮、血糖値の低下、体力回復、消化器系の改善、膣帯下、痔核、痔疾、むかつき、口内炎、関節痛、胃痛の改善などの作用があることが知られている。黒生姜は、長期にわたりヒトに摂取されてきた実績のある天然植物であって安全性が高いことから、本発明の組成物は、実用性が高く、そのままで、又は加工することにより、非経口的又は経口的な形態で種々の用途に適用可能である。 Kaempferia parviflora is a plant of the genus Kaempferia of the family Zingiberaceae, which is known to grow naturally in Southeast Asia and the like. It is known that black ginger has effects such as energizing, nourishing tonic, lowering blood sugar level, recovering physical strength, improving digestive system, subvaginal band, hemorrhoids, hemorrhoids, nausea, stomatitis, arthralgia, and stomach pain. Has been done. Since black ginger is a natural plant with a proven track record of being ingested by humans for a long period of time and is highly safe, the composition of the present invention is highly practical and is parenteral as it is or by processing. It can be applied to various uses in the form of a target or an oral form.
黒生姜の使用部位は、所望の薬理作用に寄与する成分を含む部位であれば特に限定されず、例えば、根、葉、茎、花、枝などが挙げられるが、好ましくは５，７−ジメトキシフラボン（５７ＤＭＦ）などのポリメトキシフラボノイド（ＰＭＦ）を多く含む根茎である。 The site where black ginger is used is not particularly limited as long as it contains a component that contributes to a desired pharmacological action, and examples thereof include roots, leaves, stems, flowers, and branches, but 5,7-dimethoxy is preferable. It is a rhizome rich in polymethoxyflavonoids (PMF) such as flavones (57DMF).
黒生姜は、採取した状態の未加工のものに加えて、例えば、処理物（乾燥物、裁断物など）又は黒生姜や黒生姜処理物の粉末、搾汁、抽出物などの黒生姜の加工物を包含する。ここで、抽出物とは、黒生姜における成分が抽出された物であれば特に限定されないが、例えば、黒生姜やその処理物を溶媒で抽出して得られる抽出液、その希釈液や濃縮液、又はそれらの乾燥物やその粉末が挙げられる。本発明において用いられる黒生姜は、皮膚外用組成物などの非経口用組成物や、経口用組成物などへの適用容易性を考慮すれば、黒生姜の抽出物又は搾汁などのエキスや該エキスの乾燥物であることが好ましい。 In addition to the raw ginger collected, for example, processing of black ginger such as processed products (dried products, cut products, etc.) or powders, juices, and extracts of black ginger and processed black ginger products. Including things. Here, the extract is not particularly limited as long as it is an extract of the components of black ginger, but for example, an extract obtained by extracting black ginger or a processed product thereof with a solvent, a diluted solution or a concentrated solution thereof. , Or their dried products and powders thereof. The black ginger used in the present invention is an extract of black ginger or an extract such as juice, or the extract thereof, considering the ease of application to a parenteral composition such as an external composition for skin or an oral composition. It is preferably a dried product of the extract.
黒生姜粉末は、例えば、洗浄後にスライスした黒生姜を天日又は乾燥機を用いて乾燥後、そのままで、又は適当な形状や大きさに裁断して得た処理物を、粉砕装置を用いて粉砕することで得ることができる。粉砕装置としては通常使用されるものが広く使用できるが、例えば、原料ホッパー、粉砕機、分級機、製品ホルダーなどから構成される粉砕機を用いることができる。 The black ginger powder is obtained by, for example, using a pulverizer to obtain a processed product obtained by drying the sliced black ginger after washing in the sun or using a dryer and then cutting it as it is or into an appropriate shape and size. It can be obtained by crushing. As the crushing device, those normally used can be widely used, and for example, a crusher composed of a raw material hopper, a crusher, a classifier, a product holder, and the like can be used.
黒生姜抽出物は、黒生姜やその処理物を溶媒で抽出することによって得られる。抽出に使用される溶媒としては、例えば、エタノール、メタノール、イソプロパノール、ブタノールなどの低級アルコール；酢酸エチル、酢酸メチルなどの低級エステル；アセトン；これらと水との混合溶媒などが挙げられる。水もまた抽出溶媒として挙げられ、熱水や温水などであってもよい。本発明の組成物は、ヒトが経口的に摂取する可能性があるものであることから、原料である黒生姜の抽出物は、水単独、エタノール単独又は水とエタノールとの混合溶媒（いわゆる含水エタノール）によって抽出されたものであることが好ましい。特に、２０〜８０ｖｏｌ％の濃度の含水エタノールを溶媒として使用することが好ましく、４０〜７０ｖｏｌ％の濃度の含水エタノールを溶媒として使用することがより好ましい。 Black ginger extract is obtained by extracting black ginger and its processed products with a solvent. Examples of the solvent used for extraction include lower alcohols such as ethanol, methanol, isopropanol and butanol; lower esters such as ethyl acetate and methyl acetate; acetone; and a mixed solvent of these and water. Water is also mentioned as an extraction solvent, and may be hot water, hot water, or the like. Since the composition of the present invention may be orally ingested by humans, the raw material, black ginger extract, is water alone, ethanol alone, or a mixed solvent of water and ethanol (so-called water content). It is preferably extracted with ethanol). In particular, it is preferable to use hydrous ethanol having a concentration of 20 to 80 vol% as a solvent, and it is more preferable to use hydrous ethanol having a concentration of 40 to 70 vol% as a solvent.
溶媒として混合溶媒を使用する場合は、例えば、アセトン／水（２／８〜８／２、体積比）混合物、エタノール／水（２／８〜８／２、体積比）混合物などを用いることができる。エタノール／水の場合、黒生姜の根茎に対して、その質量の２〜２０倍質量の溶媒を加え、室温又は加熱下で１０分〜４８時間程度抽出することが好ましい。 When a mixed solvent is used as the solvent, for example, an acetone / water (2/8 to 8/2, volume ratio) mixture, an ethanol / water (2/8 to 8/2, volume ratio) mixture, or the like can be used. it can. In the case of ethanol / water, it is preferable to add a solvent having a mass of 2 to 20 times the mass of the rhizome of black ginger and extract it at room temperature or under heating for about 10 minutes to 48 hours.
抽出方法は特に限定されないが、例えば、安全性、利便性及び工業化の観点から、可能な限り緩やかな条件で抽出操作を行うことが好ましい。例えば、黒生姜の部位やその乾燥物を、粉砕、破砕、細断などして、これに２〜２０倍質量の溶媒を加え、０℃〜溶媒の還流温度の範囲で１０分〜４８時間、静置、振盪、攪拌、還流などの任意の条件下にて抽出を行う。抽出作業後、ろ過、遠心分離などの固液分離操作を行い、不溶な固形物を除去する。これに、必要に応じて希釈、濃縮などの操作を行うことにより、抽出液を得る。さらに、不溶物についても同じ操作を繰り返して抽出し、その抽出液を先の抽出液と合わせて用いてもよい。これらの抽出液は、当業者が通常用いる精製方法により、さらに精製して使用してもよい。 The extraction method is not particularly limited, but for example, from the viewpoint of safety, convenience and industrialization, it is preferable to perform the extraction operation under as gentle conditions as possible. For example, the part of black ginger and its dried product are crushed, crushed, shredded, etc., and 2 to 20 times the mass of the solvent is added thereto, and the temperature ranges from 0 ° C. to the reflux temperature of the solvent for 10 minutes to 48 hours. Extraction is performed under any conditions such as standing, shaking, stirring, and reflux. After the extraction work, solid-liquid separation operations such as filtration and centrifugation are performed to remove insoluble solids. An extract is obtained by performing operations such as dilution and concentration as necessary. Further, the insoluble matter may be extracted by repeating the same operation, and the extract may be used in combination with the previous extract. These extracts may be further purified and used by a purification method usually used by those skilled in the art.
得られた抽出液は、そのままで、又は濃縮するなどして、例えば、液状物、濃縮物、さらにこれらを乾燥した乾燥物などの形態で用いることができる。乾燥は特に限定されず、例えば、噴霧乾燥、凍結乾燥、減圧乾燥、流動乾燥などの当業者が通常用いる方法により行われる。さらに、以上の方法で得られた乾燥物を、当業者に知られる方法を用いて粉末化して使用することが可能である。 The obtained extract can be used as it is or by concentrating it, for example, in the form of a liquid substance, a concentrate, or a dried product obtained by drying them. The drying is not particularly limited, and is carried out by a method usually used by those skilled in the art, such as spray drying, freeze drying, vacuum drying, and fluid drying. Further, the dried product obtained by the above method can be powdered and used by a method known to those skilled in the art.
本発明の組成物において用いられる黒生姜抽出物は特に限定されないが、例えば、抽出物全量に対する５７ＤＭＦ量の割合（５７ＤＭＦ含量）が０．０１〜５０ｗｔ％であることが好ましく、０．１〜３０ｗｔ％であることがより好ましく、０．５〜２０ｗｔ％であることがさらに好ましい。また、抽出物全量に対するＰＭＦ量（５７ＤＭＦ、３，５，７，４’−テトラメトキシフラボン及び３，５，７，３’，４’−ペンタメトキシフラボンの総量）の割合（総ＰＭＦ含量）が０．０１〜５０ｗｔ％であることが好ましく、０．１〜３０ｗｔ％であることがより好ましく、０．５〜２０ｗｔ％であることがさらに好ましい。 The black ginger extract used in the composition of the present invention is not particularly limited, but for example, the ratio of the amount of 57 DMF to the total amount of the extract (57 DMF content) is preferably 0.01 to 50 wt%, preferably 0.1 to 30 wt%. It is more preferably%, and even more preferably 0.5 to 20 wt%. In addition, the ratio (total PMF content) of the amount of PMF (total amount of 57DMF, 3,5,7,4'-tetramethoxyflavone and 3,5,7,3', 4'-pentamethoxyflavone) to the total amount of the extract is It is preferably 0.01 to 50 wt%, more preferably 0.1 to 30 wt%, and even more preferably 0.5 to 20 wt%.
本発明の組成物は、上記した黒生姜に加えて、ホップ、ケツメイシ、メリロート、ショウガ、エラスチン、没食子酸、カフェイン、オリゴ糖及びアミノ酸のうちの１種又は２種以上の特定成分を含有する。上記のうち、オリゴ糖としては、イソマルトオリゴ糖、フラクトオリゴ糖及び乳果オリゴ糖が好ましい。また、アミノ酸としては、グルタミン酸及びメチオニンを除くその他のアミノ酸であることが好ましく、酸性アミノ酸及び含硫アミノ酸を除くその他のアミノ酸であることがより好ましく、アラニン、アルギニン及びセリンがさらに好ましい。 In addition to the above-mentioned black ginger, the composition of the present invention contains one or more specific components of hops, ketsumeishi, melilote, ginger, elastin, gallic acid, caffeine, oligosaccharides and amino acids. .. Of the above, as the oligosaccharide, isomaltooligosaccharide, fructooligosaccharide and milk fruit oligosaccharide are preferable. The amino acid is preferably other amino acids other than glutamic acid and methionine, more preferably other amino acids excluding acidic amino acids and sulfur-containing amino acids, and even more preferably alanine, arginine and serine.
特定成分は、それぞれ通常知られているとおりのものであれば特に限定されない。例えば、オリゴ糖のうち、イソマルトオリゴ糖、フラクトオリゴ糖及び乳果オリゴ糖は通常知られているとおりの糖類であり、これらは固形物、液状物などの形状のものとして、黒生姜と組み合わせられ得る。また、アミノ酸のうち、アラニン、アルギニン及びセリンは通常知られているとおりのアミノ酸であり、Ｄ体及びＬ体のいずれでもよく、形状も特に限定されないが、Ｌ体の固形物であることが好ましい。 The specific components are not particularly limited as long as they are as usually known. For example, among oligosaccharides, isomaltooligosaccharides, fructooligosaccharides and milk fruit oligosaccharides are commonly known saccharides, which can be combined with black ginger in the form of solids, liquids and the like. .. Among the amino acids, alanine, arginine and serine are amino acids as are usually known, and may be either D-form or L-form, and the shape is not particularly limited, but it is preferably an L-form solid substance. ..
同様に、ホップ、ケツメイシ、メリロート、ショウガ、エラスチン、没食子酸及びカフェインについても通常知られているものであれば、形状については特に限定さない。また、これらのうち、天然物である特定成分については、使用される部位がそれらの一部であっても全部であってもどちらでもよい。 Similarly, hops, ketsumeishi, melilote, ginger, elastin, gallic acid and caffeine are not particularly limited in shape as long as they are generally known. In addition, among these, with respect to a specific component that is a natural product, the part used may be a part or all of them.
特定成分の中で、ホップ、ケツメイシ、メリロート及びショウガの天然物については、それぞれ通常知られているとおりのものであれば特に限定されない。例えば、ホップはセイヨウカラハナソウ（学名：Ｈｕｍｕｌｕｓ ｌｕｐｕｌｕｓ）として知られており、例えば、その花（毬花）、種子、果実、茎葉、根などの部位を用いることができるが、毬花を用いることが好ましい。ケツメイシはエビスグサ（学名：Ｓｅｎｎａ ｏｂｔｕｓｉｆｏｌｉａ）の種子である。メリロートはセイヨウエビラハギ（学名：Ｍｅｌｉｌｏｔｕｓ ｏｆｆｉｃｉｎａｌｉｓ）として知られており、例えば、その花、種子、果実、茎葉、根などの部位を用いることができるが、花又は茎葉を用いることが好ましい。生姜はショウガ（学名：Ｚｉｎｇｉｂｅｒ ｏｆｆｉｃｉｎａｌｅ）として知られており、例えば、その花、種子、果実、茎葉、根（根茎）などの部位を用いることができるが、根茎を用いることが好ましい。 Among the specific components, the natural products of hops, ketsumeishi, melilote and ginger are not particularly limited as long as they are usually known. For example, hops are known as Hops (scientific name: Humulus lupulus ), and for example, parts such as their flowers (barb flowers), seeds, fruits, foliage, roots, etc. can be used, but it is possible to use barn flowers. preferable. Ketsumeishi is the seed of sicklepod (scientific name: Senna obtusifolia ). Melirot is known as yellow sweet clover (scientific name: Melilotus officinalis ), and for example, parts such as its flowers, seeds, fruits, foliage, and roots can be used, but it is preferable to use flowers or foliage. Ginger ginger (scientific name: Zingiber officinale) is known as, for example, its flowers, seeds, fruits, stems and leaves, can be used site such as roots (rhizomes), it is preferable to use a rhizome.
特定成分は、黒生姜と同様に様々な形態で用いることができ、例えば、天然物の場合は採取した状態の未加工のものに加えて、処理物（乾燥物、裁断物など）又はそれらの粉末、搾汁、抽出物などの加工物であり得る。特定成分の加工物は、本明細書の黒生姜の加工物に関する記載を参照して製造し得る。 The specific component can be used in various forms like black ginger. For example, in the case of a natural product, in addition to the raw product in the collected state, a processed product (dried product, cut product, etc.) or their It can be a processed product such as powder, juice, extract. Processed products of specific components can be produced with reference to the description of the processed products of black ginger herein.
特定成分は、当業者により通常知られている方法によって製造したものでもよいし、市場に流通しているものであってもよい。 The specific ingredient may be produced by a method generally known to those skilled in the art, or may be commercially available.
特定成分は、各々単独ではほとんどＵＣＰ１発現促進作用又は褐色脂肪細胞分化促進作用を示さない。しかし、驚くべきことに、黒生姜と組み合わせることで、少なくともこれらのいずれかの作用を示すようになる。したがって、黒生姜と、特定成分との組み合わせによるＵＣＰ１発現促進作用及び褐色脂肪細胞分化促進作用は、相加的というよりも、相乗的な作用であるということができる。 Each of the specific components shows almost no UCP1 expression promoting action or brown adipocyte differentiation promoting action by itself. However, surprisingly, when combined with black ginger, it will exhibit at least one of these effects. Therefore, it can be said that the UCP1 expression promoting action and the brown adipocyte differentiation promoting action by the combination of black ginger and a specific component are synergistic actions rather than additive actions.
本明細書における「発現促進作用」とは、例えば、ＵＣＰ１発現促進作用の場合、被験体におけるＵＣＰ１遺伝子の発現量を促進すること、ＵＣＰ１タンパク質の翻訳量を増大すること及びＵＣＰ１を活性化することのうち少なくともいずれか１つの作用をいう。また、褐色脂肪細胞活性化作用とは、褐色脂肪細胞を活性化すること及び褐色脂肪細胞数を増加させることのうち少なくともいずれか１つの作用をいう。 The term "expression-promoting action" as used herein means, for example, in the case of UCP1 expression-promoting action, promoting the expression level of the UCP1 gene in a subject, increasing the translation amount of the UCP1 protein, and activating UCP1. It refers to the action of at least one of them. Further, the brown adipocyte activating action refers to at least one of activating brown adipocytes and increasing the number of brown adipocytes.
ＵＣＰ１発現促進作用について、非特許文献１に記載されているとおり、肥満動物ではＵＣＰ１の機能が低下していること、多食しても肥満しない動物はＵＣＰ１が増加していること、人為的にＵＣＰ１の発現を低下させたマウスは肥満し高発現マウスは痩せることが知られている。したがって、ＵＣＰ１発現促進作用により、抗肥満効果が期待でき、実際にＵＰＣ１発現促進作用を有する物質は、白色脂肪細胞での脂肪分解を促すと同時にＵＣＰ１を活性化して、遊離した脂肪酸を熱に変え、最終的に体脂肪を減少させることができる。 Regarding the UCP1 expression promoting action, as described in Non-Patent Document 1, the function of UCP1 is decreased in obese animals, UCP1 is increased in animals that do not become obese even if they eat a lot, and UCP1 is artificially increased. It is known that mice with reduced expression of thermogenin are obese and mice with high expression are thin. Therefore, an anti-obesity effect can be expected due to the UCP1 expression promoting action, and a substance having the UPC1 expression promoting action promotes lipolysis in white adipocytes and at the same time activates UCP1 to convert liberated fatty acids into heat. Finally, body fat can be reduced.
熱産生促進作用とは、例えば、褐色脂肪細胞による中性脂質からの熱産生を促進する作用をいう。中性脂質低下作用とは、例えば、中性脂質を分解して生体内における中性脂質の全量を低下させる作用をいう。皮脂抑制作用とは、例えば、皮脂の発生を抑制する作用をいう。脂肪代謝促進作用とは、例えば、肥満状態を形成する脂肪細胞や脂肪組織を小型の正常な脂肪細胞に質的変換する作用をいう。体脂肪減少作用とは、例えば、遊離した脂肪酸を熱に変えることにより体脂肪を減少させる作用をいう。代謝促進作用及び抗肥満作用とは、例えば、体脂肪を減少するように代謝を促進する作用及び該作用により肥満になることを抑制する作用をいう。エネルギー産生促進作用とは、例えば、褐色脂肪細胞による中性脂質からの熱産生を通じてエネルギーを産生する作用をいう。本段落における各作用はそれぞれ記載した意味の作用を含むが、その他の作用機序により実現されるものも包含する。 The heat production promoting action means, for example, an action of promoting heat production from neutral lipids by brown adipocytes. The triglyceride lowering action means, for example, an action of decomposing triglyceride to lower the total amount of triglyceride in the living body. The sebum suppressing action means, for example, an action of suppressing the generation of sebum. The action of promoting fat metabolism refers to, for example, the action of qualitatively converting adipocytes and adipose tissue forming an obese state into small normal adipocytes. The body fat-reducing action refers to, for example, the action of reducing body fat by converting free fatty acids into heat. The metabolism-promoting action and the anti-obesity action refer to, for example, an action of promoting metabolism so as to reduce body fat and an action of suppressing obesity due to the action. The energy production promoting action refers to an action of producing energy through, for example, heat production from neutral lipids by brown adipocytes. Each action in this paragraph includes actions with the meanings described, but also includes those realized by other mechanisms of action.
本発明の抗肥満用組成物などの抗疾患組成物が奏する抗疾患効果とは、例えば、抗肥満用組成物が奏する抗肥満効果の場合、被験体における現在又は将来の肥満若しくは肥満症であるとされる状態になることを抑制若しくは遅滞又はその状態を改善することをいう。また、インスリン抵抗性とは、肝臓、脂肪細胞、骨格筋などで、インスリンの主な作用である糖の吸収促進作用が弱っている状態をいう。抗インスリン抵抗性効果とは、被験体におけるＳＳＰＧ（Ｓｔｅａｄｙ−ｓｔａｔｅ ｐｌａｓｍａ ｇｌｕｃｏｓｅ）法などによる現在又は将来のインスリン抵抗性の指標となる値がより悪化することを抑制若しくは遅滞又はその値を改善することをいう。 The anti-disease effect exerted by an anti-disease composition such as the anti-obesity composition of the present invention is, for example, the current or future obesity or obesity in a subject in the case of the anti-obesity effect exerted by the anti-obesity composition. It means to suppress or delay the condition or to improve the condition. Insulin resistance refers to a state in which the main action of insulin, which promotes absorption of sugar, is weakened in the liver, adipocytes, skeletal muscle, and the like. The anti-insulin resistance effect is to suppress or delay the deterioration of the current or future index value of insulin resistance by the SSPG (Steady-state plasma glucose) method or the like in a subject, or to improve the value thereof. To say.
肥満は様々な疾病の原因となることが知られており、そのような疾病としては２型糖尿病、高血圧症、高脂血症などが挙げられる。さらにこれらの疾病を通じ、脳卒中や虚血性心疾患などがもたらされる場合もある。肥満状態になると、脂肪細胞の肥大が認められ、ＴＮＦ−α及び遊離脂肪酸（ＦＦＡ）が分泌され、これらが筋肉細胞や肝臓細胞などのインスリンの標的細胞での糖の取り込みを阻害するとともに、インスリンの働きを促進するアディポネクチンの分泌が抑制され、細胞レベルでインスリン感受性の低下を引き起こし、インスリン抵抗性が生じる。上記の肥満によってもたらされる疾病は、インスリン抵抗性に基づく、一連の代謝異常状態とみられている。そこで、本発明の組成物を用いることにより、肥満や肥満症と関連付けられる２型糖尿病、高血圧症、高脂血症などの疾病を予防又は改善することが可能である。 Obesity is known to cause a variety of illnesses, including type 2 diabetes, hypertension, and hyperlipidemia. In addition, these diseases may lead to stroke and ischemic heart disease. In the obese state, hypertrophy of adipocytes is observed, and TNF-α and free fatty acid (FFA) are secreted, which inhibit the uptake of sugar in insulin target cells such as muscle cells and liver cells, and insulin. The secretion of adiponectin, which promotes the action of insulin, is suppressed, causing a decrease in insulin sensitivity at the cellular level, resulting in insulin resistance. The diseases caused by the above obesity are considered to be a series of metabolic disorders based on insulin resistance. Therefore, by using the composition of the present invention, it is possible to prevent or ameliorate diseases such as type 2 diabetes, hypertension, and hyperlipidemia associated with obesity and obesity.
ここで、２型糖尿病の予防及び改善とは、糖尿病の状態又は境界域の状態になることを抑制若しくは遅滞又はそれらの状態から正常域といわれる状態に近づけることをいう。高血圧症の予防及び改善とは、高血圧とされる状態又は境界域の状態になることを抑制若しくは遅滞又はその状態から正常域といわれる状態に近づけることをいう。高脂血症の予防及び改善とは、高脂血症の状態又は境界域の状態になることを抑制若しくは遅滞又はその状態から正常域といわれる状態に近づけることをいう。 Here, prevention and amelioration of type 2 diabetes means suppressing or delaying the state of diabetes mellitus or the state of the borderline area, or approaching the state called the normal range from those states. Prevention and improvement of hypertension means suppressing or delaying the state of hypertension or the state of the borderline, or bringing the state closer to the state called the normal range. Prevention and improvement of hyperlipidemia means suppressing or delaying the state of hyperlipidemia or the state of the borderline, or bringing the state closer to the state called the normal range.
本発明の組成物の製造方法は特に限定されず、例えば、室温や加温下で、黒生姜と、特定成分とを混合することにより、固形状組成物とすることができる。または、この固形状組成物を、水などの溶媒に溶解させて液状組成物とすることができる。さらに、黒生姜や特定成分の液状物に、他の固形状成分を加えて混合することにより液状組成物とすることができる。なお、得られた液状組成物は、乾燥処理を経て、粉末化しても良い。この場合の乾燥処理の方法としては、噴霧乾燥、凍結乾燥などが挙げられるが、これらに限定されない。 The method for producing the composition of the present invention is not particularly limited, and for example, a solid composition can be obtained by mixing black ginger and a specific component at room temperature or heating. Alternatively, this solid composition can be dissolved in a solvent such as water to obtain a liquid composition. Further, a liquid composition can be obtained by adding other solid components to a liquid substance of black ginger or a specific component and mixing them. The obtained liquid composition may be powdered after undergoing a drying treatment. Examples of the drying treatment method in this case include, but are not limited to, spray drying and freeze drying.
本発明において、黒生姜抽出物及び特定成分の含有量は特に限定されず、例えば、これらの質量比（［黒生姜］：［特定成分の総量］）が１：０．００１〜２０であり、好ましくは１：０．０１〜１０であり、より好ましくは１：０．０５〜５である。 In the present invention, the contents of the black ginger extract and the specific component are not particularly limited, and for example, their mass ratio ([black ginger]: [total amount of the specific component]) is 1: 0.001 to 20. It is preferably 1: 0.01 to 10, and more preferably 1: 0.05 to 5.
本発明の組成物は、用途に応じて、そのままで、又は他の成分と混合して使用することができる。このように、本発明の組成物は、黒生姜及び特定成分の他に、本発明の目的を達成し得る限り、種々のものを配合できる。 The composition of the present invention can be used as it is or mixed with other components depending on the intended use. As described above, in addition to black ginger and specific components, various compositions of the present invention can be blended as long as the object of the present invention can be achieved.
例えば、本発明の組成物には、賦形剤、増量剤、結合剤、増粘剤、乳化剤、着色料、香料、香油などの通常の加工に使用される添加物をさらに含有することができる。添加物の使用量は、本発明の課題の解決を妨げない限り特に限定されず、適宜調整される。 For example, the compositions of the present invention may further contain additives used in conventional processing such as excipients, bulking agents, binders, thickeners, emulsifiers, colorants, fragrances and perfume oils. .. The amount of the additive used is not particularly limited as long as it does not interfere with the solution of the problem of the present invention, and is appropriately adjusted.
本発明の組成物は、通常用いられる形態であれば特に制限されず、例えば、液状、ローション状、ムース状、ゲル状、乳液状、懸濁液状、クリーム状、軟膏状、シート状、エアゾール状、スプレー状、スティック状、粉状、粒状、顆粒状、錠状、棒状、板状、ブロック状、固形状、ペースト状、カプセル状、カプレット状などの各形態を採り得る。 The composition of the present invention is not particularly limited as long as it is in a commonly used form, and is, for example, liquid, lotion, mousse, gel, milky, suspension, cream, ointment, sheet, aerosol. , Spray-like, stick-like, powder-like, granular, granular-like, tablet-like, stick-like, plate-like, block-like, solid-like, paste-like, capsule-like, caplet-like and the like.
本発明の組成物は、非経口用組成物として、例えば、化粧品に適した形態として使用することができる。すなわち、本発明の組成物の一態様は、化粧用組成物である。例えば、本発明の組成物は、そのままで、又は通常化粧品の加工に使用される添加物と混合して、ローション剤、乳剤、ゲル剤、クリーム剤、軟膏剤などの種々の形態に加工され得る。具体的には、化粧水、化粧クリーム、乳液、クリーム、パック、ヘアトニック、ヘアクリーム、シャンプー、ヘアリンス、トリートメント、洗顔剤、ファンデーション、育毛剤、水性軟膏、スプレーなどとして利用できる。 The composition of the present invention can be used as a parenteral composition, for example, in a form suitable for cosmetics. That is, one aspect of the composition of the present invention is a cosmetic composition. For example, the compositions of the present invention can be processed into various forms such as lotions, emulsions, gels, creams, ointments, etc., either as is or mixed with additives commonly used in the processing of cosmetics. .. Specifically, it can be used as a lotion, a cosmetic cream, a milky lotion, a cream, a pack, a hair tonic, a hair cream, a shampoo, a hair rinse, a treatment, a facial cleanser, a foundation, a hair restorer, an aqueous ointment, and a spray.
本発明の組成物に含有される黒生姜の含有量は、ＵＣＰ１発現促進作用及び／又は褐色脂肪細胞分化促進作用が認められる量であれば特に限定されないが、経口用組成物としては、例えば、０．０００１ｗｔ％以上、好ましくは０．００１ｗｔ％以上であり、化粧品などの非経口用組成物としては、例えば、０．００００１ｗｔ％以上、好ましくは０．０００１ｗｔ％以上である。 The content of black ginger contained in the composition of the present invention is not particularly limited as long as it has a UCP1 expression promoting action and / or a brown adipocyte differentiation promoting action, but examples of the oral composition include, for example. It is 0.0001 wt% or more, preferably 0.001 wt% or more, and for a parenteral composition such as cosmetics, for example, it is 0.00001 wt% or more, preferably 0.0001 wt% or more.
本発明の組成物は、経口用組成物である場合、黒生姜と特定成分とを含有することにより、旨味改善作用を有するものを包含する。 In the case of an oral composition, the composition of the present invention includes a composition having an umami-improving effect by containing black ginger and a specific component.
本発明の組成物の具体的な態様として、例えば、黒生姜を４０〜９０ｗｔ％、特定成分のいずれか１種の成分を１０〜６０ｗｔ％の割合で含有する組成物が挙げられる。このうち、黒生姜を５０〜８０ｗｔ％、特定成分のいずれか１種の成分を２０〜５０ｗｔ％の割合で含有する組成物がより好ましい。 Specific embodiments of the composition of the present invention include, for example, a composition containing 40 to 90 wt% of black ginger and 10 to 60 wt% of any one of the specific components. Of these, a composition containing 50 to 80 wt% of black ginger and 20 to 50 wt% of any one of the specific components is more preferable.
本発明の組成物の別の具体的な態様として、黒生姜を４０〜９０ｗｔ％、特定成分のいずれか２種の成分を合計で１０〜６０ｗｔ％の割合で含有する組成物が挙げられる。このうち、黒生姜を５０〜８０ｗｔ％、該２種の成分のうち一方の成分を１０〜３０ｗｔ％、他方の成分を１０〜２０ｗｔ％の割合で含有する組成物が挙げられる。 As another specific embodiment of the composition of the present invention, there is a composition containing 40 to 90 wt% of black ginger and 10 to 60 wt% of any two components of the specific component in total. Among these, a composition containing 50 to 80 wt% of black ginger, 10 to 30 wt% of one of the two components, and 10 to 20 wt% of the other component can be mentioned.
本発明の組成物の別の具体的な態様として、黒生姜を４０〜９０ｗｔ％、特定成分のいずれか３種の成分を合計で１０〜６０ｗｔ％の割合で含有する組成物が挙げられる。このうち、黒生姜を５０〜８０ｗｔ％、該３種の成分のうち１種目の成分を７．５〜２０ｗｔ％、２種目の成分を７．５〜２０ｗｔ％、３種目の成分を５〜１０ｗｔ％の割合で含有する組成物が挙げられる。 As another specific embodiment of the composition of the present invention, there is a composition containing 40 to 90 wt% of black ginger and 10 to 60 wt% of any three components of the specific component in total. Of these, 50 to 80 wt% of black ginger, 7.5 to 20 wt% of the first component of the three components, 7.5 to 20 wt% of the second component, and 5 to 10 wt% of the third component. Examples of the composition contain%.
上記した本発明の組成物の具体的な態様は、黒生姜及び特定成分の総質量に対する割合を示すものである。すなわち、上記の黒生姜及び特定成分の割合は、添加物を除いた、黒生姜及び特定成分の総質量に対する、黒生姜及び特定成分のそれぞれの割合を示すものである。 A specific aspect of the composition of the present invention described above is a ratio of black ginger and a specific component to the total mass. That is, the above-mentioned ratio of black ginger and specific component indicates the ratio of each of black ginger and specific component to the total mass of black ginger and specific component excluding additives.
以下、本発明の組成物の具体的態様に係る配合例を示すが、本発明はこれら配合例に限定されるものではなく、本発明の課題を解決し得る限り、本発明は種々の態様をとることができる。 Hereinafter, formulation examples relating to specific aspects of the composition of the present invention will be shown, but the present invention is not limited to these formulation examples, and the present invention has various aspects as long as the problems of the present invention can be solved. Can be taken.
（配合例１：化粧水）
全体を１００質量部として、黒生姜抽出物 ０．０１質量部、生姜抽出物 ０．０１質量部、ケツメイシ ０．０１質量部、グリセリン １０質量部、ジグリセリン ３質量部、１，３−ブチレングリコール １２質量部、ペンチレングリコール ３質量部、ヒアルロン酸ナトリウム ０．１質量部、クエン酸 ０．０１質量部、クエン酸ナトリウム ０．０２質量部、キサンタンガム ０．１質量部、メチルパラベン ０．１５質量部、カルボマー ０．２質量部、水酸化ナトリウム ０．０３質量部及び水 残部を混合して、化粧水の態様で本発明の組成物を調製した。
(Formulation example 1: Toner)
With 100 parts by mass as a whole, 0.01 part by mass of black ginger extract, 0.01 part by mass of ginger extract, 0.01 part by mass of ketsumeishi, 10 parts by mass of glycerin, 3 parts by mass of diglycerin, 1,3-butylene glycol 12 parts by mass, 3 parts by mass of pentylene glycol, 0.1 parts by mass of sodium hyaluronate, 0.01 parts by mass of citric acid, 0.02 parts by mass of sodium citrate, 0.1 parts by mass of xanthan gum, 0.15 parts by mass of methylparaben , 0.2 parts by mass of carbomer, 0.03 part by mass of sodium hydroxide and the water residue were mixed to prepare the composition of the present invention in the form of cosmetic water.
（配合例２：シャンプー）
全体を１００質量部として、黒生姜抽出物 ０．０１質量部、ホップ抽出物 ０．０２質量部、カフェイン ０．０１重量部、ラウレス硫酸ナトリウム ７．５質量部、コカミドプロピルベタイン ４．２質量部、コカミドＤＥＡ ３質量部、１，３−ブチレングリコール ０．１質量部、ポリクオタニウム−１０ ０．２２５質量部、クエン酸 ０．１５質量部、クエン酸ナトリウム ０．０５質量部、フェノキシエタノール ０．９質量部及び水 残部を混合して、シャンプーの態様で本発明の組成物を調製した。
(Formulation example 2: shampoo)
Taking the whole as 100 parts by mass, 0.01 part by mass of black ginger extract, 0.02 part by mass of hop extract, 0.01 part by mass of caffeine, 7.5 parts by mass of sodium laureth sulfate, 4.2 by mass of cocamidopropyl betaine. Mass, Cocamide DEA 3 mass, 1,3-butylene glycol 0.1 mass, Polyquaternium-10 0.225 mass, Citric acid 0.15 mass, Sodium citrate 0.05 mass, Phenoxyethanol 0. The composition of the present invention was prepared in the form of shampoo by mixing 9 parts by mass and the water residue.
（配合例３：石鹸）
全体を１００質量部として、黒生姜粉砕物 ０．５質量部、メリロート抽出物 ０．２質量部、エラスチン ０．１重量部、グリセリン ２質量部、オリーブ油 １質量部、ＥＤＴＡ−４ナトリウム ０．１質量部、エチドロン酸４ナトリウム ０．２質量部及び石ケン素地 残部を混合及び固化することにより、石鹸の態様で本発明の組成物を調製した。
(Formulation example 3: Soap)
With 100 parts by mass as a whole, 0.5 parts by mass of crushed black ginger, 0.2 parts by mass of melilot extract, 0.1 parts by mass of elastin, 2 parts by mass of glycerin, 1 part by mass of olive oil, 0.1 parts of EDTA-4 sodium The composition of the present invention was prepared in the form of soap by mixing and solidifying parts by mass, 0.2 parts by mass of tetrasodium etidronate and the rest of the soap base.
（配合例４：乳液）
全体を１００質量部として、黒生姜抽出物 ０．１質量部、アラニン ０．１質量部、アルギニン ０．１質量部、ショ糖脂肪酸エステル ３質量部、グリセリン １２質量部、スクワラン ６質量部、ジメチルシリコーンオイル ２４質量部、ポリプロピレングリコール １質量部、増粘剤 ０．０６質量部、フェノキシエタノール ０．２質量部、エタノール ５質量部、水酸化ナトリウム ０．０１質量部及び精製水 残部を混合して、乳液の態様で本発明の組成物を調製した。
(Formulation example 4: emulsion)
With 100 parts by mass as a whole, 0.1 part by mass of black ginger extract, 0.1 part by mass of alanine, 0.1 part by mass of arginine, 3 parts by mass of sucrose fatty acid ester, 12 parts by mass of glycerin, 6 parts by mass of squalane, dimethyl Mix 24 parts by mass of silicone oil, 1 part by mass of polypropylene glycol, 0.06 parts by mass of thickener, 0.2 parts by mass of phenoxyethanol, 5 parts by mass of ethanol, 0.01 parts by mass of sodium hydroxide and the balance of purified water. The compositions of the present invention were prepared in the form of emulsion.
（配合例５：化粧用クリーム）
全体を１００質量部として、黒生姜抽出物 ０．１質量部、イソマルトオリゴ糖 ０．１質量部、フラクトオリゴ糖 ０．１重量部、スクワラン １５．０質量部、ミリスチン酸オクチルドデシル ４．０質量部、水素添加大豆リン脂質 ０．２質量部、ブチルアルコール ２．４質量部、硬化油 １．５質量部、ステアリン酸 １．５質量部、親油型モノステアリン酸グリセリン １．５質量部、モノステアリン酸ポリグリセリル ０．５質量部、ベヘニルアルコール ０．８質量部、モノミリスチン酸ポリグリセリル ０．７質量部、サラシミツロウ ０．３質量部、ｄ−δ−トコフェロール ０．１質量部、メチルパラベン ０．３質量部、Ｃ１０〜３０アルキル変性カルボキシビニルポリマー ０．２質量部、カルボキシビニルポリマー ０．１質量部、１，３−ブタンジオール １８．０質量部、水酸化ナトリウム ０．１質量部及び精製水 残部を混合して、化粧用クリームの態様で本発明の組成物を調製した。
(Formulation example 5: Cosmetic cream)
With 100 parts by mass as a whole, 0.1 parts by mass of black ginger extract, 0.1 parts by mass of isomaltooligosaccharide, 0.1 part by mass of fructo-oligosaccharide, 15.0 parts by mass of squalane, 4.0 parts by mass of octyldodecyl myristate , Hydrogenated soybean phospholipid 0.2 parts by mass, butyl alcohol 2.4 parts by mass, hardening oil 1.5 parts by mass, stearic acid 1.5 parts by mass, proo oil type glycerin monostearate 1.5 parts by mass, mono Polyglyceryl stearate 0.5 parts by mass, behenyl alcohol 0.8 parts by mass, polyglyceryl monomyristate 0.7 parts by mass, salashimitsuro 0.3 parts by mass, d-δ-tocopherol 0.1 parts by mass, methylparaben 0.3 parts by mass 0.2 parts by mass of C10-30 alkyl modified carboxyvinyl polymer, 0.1 part by mass of carboxyvinyl polymer, 18.0 parts by mass of 1,3-butanediol, 0.1 parts by mass of sodium hydroxide and the balance of purified water. Mix to prepare the compositions of the invention in the form of cosmetic creams.
（配合例６：パック剤）
全体を１００質量部として、黒生姜抽出物 ０．１質量部、没食子酸 ０．０１質量部、ポリビニルアルコール ２０．０質量部、グリセリン ５．０質量部、エタノール ２０．０質量部、カオリン ６．０質量部、防腐剤 ０．２質量部、香料 ０．１質量部及び精製水 残部を混合して、パック剤の態様で本発明の組成物を調製した。
(Formulation example 6: Packing agent)
6. With 100 parts by mass as a whole, 0.1 part by mass of black ginger extract, 0.01 part by mass of gallic acid, 20.0 parts by mass of polyvinyl alcohol, 5.0 parts by mass of glycerin, 20.0 parts by mass of ethanol, and kaolin. The composition of the present invention was prepared in the form of a pack by mixing 0 parts by mass, 0.2 parts by mass of the preservative, 0.1 parts by mass of the fragrance and the balance of purified water.
（配合例７：錠剤）
全体を１００質量部として、黒生姜粉末 １０質量部、ショウガ抽出物 ８質量部、カフェイン５重量部、メリロート ５質量部、結晶性セルロース ２０質量部、乳糖 ５０質量部、ステアリン酸マグネシウム ４質量部及びコーンスターチ 残部を混合及び打錠することにより、錠剤の態様で本発明の組成物を調製した。
(Formulation Example 7: Tablet)
With 100 parts by mass as a whole, 10 parts by mass of black ginger powder, 8 parts by mass of ginger extract, 5 parts by mass of caffeine, 5 parts by mass of melilot, 20 parts by mass of crystalline cellulose, 50 parts by mass of lactose, 4 parts by mass of magnesium stearate. And the composition of the present invention was prepared in the form of tablets by mixing and tableting the rest of the corn starch.
（配合例８：錠剤）
全体を１００質量部として、黒生姜粉末 １０質量部、ケツメイシ末 ８質量部、メリロート ５質量部、イソマルトオリゴ糖 ０．５質量部、フラクトオリゴ糖 ０．５質量部、結晶性セルロース ２０質量部、乳糖 ５０質量部、ステアリン酸マグネシウム ４質量部及びコーンスターチ 残部を混合及び打錠することにより、錠剤の態様で本発明の組成物を調製した。
(Formulation Example 8: Tablet)
With 100 parts by mass as a whole, 10 parts by mass of black ginger powder, 8 parts by mass of powdered ketsumeishi, 5 parts by mass of melilot, 0.5 parts by mass of isomaltooligosaccharide, 0.5 parts by mass of fructo-oligosaccharide, 20 parts by mass of crystalline cellulose, lactose The composition of the present invention was prepared in the form of a tablet by mixing and tableting 50 parts by mass, 4 parts by mass of magnesium stearate and the balance of corn starch.
（配合例９：顆粒剤）
全体を１００質量部として、黒生姜粉末 １０質量部、ホップ末 １５質量部、ケツメイシ抽出物 ５質量部、乳糖 １０質量部、ステアリン酸カルシウム １質量部及び結晶性セルロース 残部を混合及び顆粒化することにより、顆粒剤の態様で本発明の組成物を調製した。
(Formulation Example 9: Granules)
By mixing and granulating 10 parts by mass of black ginger powder, 15 parts by mass of hop powder, 5 parts by mass of ketsumeishi extract, 10 parts by mass of lactose, 1 part by mass of calcium stearate and the balance of crystalline cellulose, taking the whole as 100 parts by mass. , The composition of the present invention was prepared in the form of granules.
（配合例１０：カプセル剤）
全体を１００質量部として、黒生姜抽出物 １０質量部、生姜抽出物 ２０質量部、エラスチン５質量部、レシチン ８質量部及びオリーブ油 残部を混合して調製したものを内容液として、これをカプセル殻に内包することにより、カプセル剤の態様で本発明の組成物を調製した。
(Formulation Example 10: Capsule)
A capsule shell prepared by mixing 10 parts by mass of black ginger extract, 20 parts by mass of ginger extract, 5 parts by mass of elastin, 8 parts by mass of lecithin and the balance of olive oil with the whole as 100 parts by mass. The composition of the present invention was prepared in the form of a capsule by encapsulating in.
（配合例１１：液剤）
全体を１００質量部として、黒生姜エキス粉末 ０．８４質量部、アルギニン １質量部、アラニン １質量部、果糖ブドウ糖液糖 １０質量部、クエン酸 １質量部、安息香酸ナトリウム ０．０２質量部、香料製剤 ２質量部、スクラロース ０．０５質量部、アセスルファムカリウム ０．０３質量部、及び精製水 残部を混合して、液剤の態様で本発明の組成物を調製した。
(Formulation Example 11: Liquid agent)
With 100 parts by mass as a whole, 0.84 parts by mass of black ginger extract powder, 1 part by mass of arginine, 1 part by mass of alanine, 10 parts by mass of fructose-dextrose liquid sugar, 1 part by mass of citric acid, 0.02 parts by mass of sodium benzoate, The composition of the present invention was prepared in the form of a liquid preparation by mixing 2 parts by mass of a fragrance preparation, 0.05 parts by mass of sclarose, 0.03 parts by mass of acesulfam potassium, and the balance of purified water.
［１．黒生姜抽出物と副素材との組み合わせによるＵＣＰ１発現量の影響評価］
（１）黒生姜粉砕物の製造
黒生姜の根茎を洗浄後、１〜１０ｍｍ程度にスライスし、１日天日干しにした。その後、４０〜１００℃に設定したオーブン乾燥機で４〜６時間乾燥し、粗粉砕後、１３０〜２００℃で５〜２０秒間殺菌を行った。殺菌した粗粉砕物を粉砕機によって粉砕し、黒生姜の根茎粉砕物を得た。同様の方法により、黒生姜の茎粉砕物、葉粉砕物及び花粉砕物を得た。これらを黒生姜粉砕物とした。
[1. Evaluation of the effect of UCP1 expression level by the combination of black ginger extract and secondary material]
(1) Production of crushed black ginger The rhizome of black ginger was washed, sliced to about 1 to 10 mm, and dried in the sun for one day. Then, it was dried in an oven dryer set at 40 to 100 ° C. for 4 to 6 hours, roughly pulverized, and sterilized at 130 to 200 ° C. for 5 to 20 seconds. The sterilized coarse crushed product was crushed by a crusher to obtain a crushed rhizome of black ginger. By the same method, crushed stems, crushed leaves and crushed flowers of black ginger were obtained. These were made into crushed black ginger.
（２）黒生姜抽出物の製造
上記した方法により得た黒生姜粉砕物 ３００ｇを秤量し、６０ｖｏｌ％エタノール ３Ｌと共に三角フラスコに入れた。途中で何回か攪拌しながら室温で２４時間静置して１回目の抽出を行った。これを減圧ろ過して、１回目の抽出液を得た。減圧ろ過後の残渣を６０ｖｏｌ％エタノール ３Ｌに浸漬して、室温で２４時間静置して２回目の抽出を行った。これを減圧ろ過して、２回目の抽出液を得た。これら１回目及び２回目の抽出液を併せた抽出混合液を減圧濃縮して黒生姜抽出物を得た。得られた黒生姜抽出物は、５７ＤＭＦ含量が９．２７ｗｔ％であった。
(2) Production of Black Ginger Extract 300 g of crushed black ginger obtained by the above method was weighed and placed in an Erlenmeyer flask together with 3 L of 60 vol% ethanol. The first extraction was performed by allowing the mixture to stand at room temperature for 24 hours with stirring several times on the way. This was filtered under reduced pressure to obtain the first extract. The residue after vacuum filtration was immersed in 3 L of 60 vol% ethanol and allowed to stand at room temperature for 24 hours for the second extraction. This was filtered under reduced pressure to obtain a second extract. The extraction mixture obtained by combining the first and second extracts was concentrated under reduced pressure to obtain a black ginger extract. The obtained black ginger extract had a 57DMF content of 9.27 wt%.
（３）被験物質
ホップ、ケツメイシ、メリロートエキス、ショウガ、エラスチン、没食子酸、カフェイン、アルギニン、アラニン、イソマルトオリゴ糖、フラクトオリゴ糖、グルタミン酸及びメチオニンを被験物質として用いた。
(3) Test substances Hop, ketsumeishi, melilot extract, ginger, elastin, gallic acid, caffeine, arginine, alanine, isomaltooligosaccharide, fructooligosaccharide, glutamic acid and methionine were used as test substances.
（４）コラゲナーゼ溶液の調製
コラゲナーゼが０．２％（Ｗ／Ｖ）、ＢＳＡが１％（Ｗ／Ｖ）となるように調製したＤＭＥＭ培地を、室温で１時間振盪することによって、コラゲナーゼ溶液を調製した。
(4) Preparation of Collagenase Solution The collagenase solution is prepared by shaking the DMEM medium prepared so that the collagenase is 0.2% (W / V) and the BSA is 1% (W / V) at room temperature for 1 hour. Prepared.
（５）褐色脂肪細胞液の調製
ＩＣＲマウス（九動）をジエチルエーテルで安楽殺した後、背部から褐色脂肪組織を摘出した。得られた褐色脂肪組織から、ピンセットを用いて、褐色脂肪の周辺に付着している脂肪組織、血管、筋肉などを取り除いた後、褐色脂肪をＤＭＥＭ中で３回洗浄した。次いで、コラゲナーゼ溶液に褐色脂肪を浸し、溶液中で褐色脂肪をハサミで細かく切り刻む細断処理に供した。細断処理した褐色脂肪をコラゲナーゼ溶液中で、３７℃で１時間インキュベートすることにより細胞分散液を得た。得られた細胞分散液を、１００μｍの孔径のセルストレイナーでろ過し、次いで遠心処理（８００ｒｐｍ、５ｍｉｎ、２０℃）に供した。次いで、沈殿した細胞をＤＭＥＭで懸濁して、細胞懸濁液を得た。次いで、オートクレーブで滅菌処理した２５μｍフィルターを用いて、得られた細胞懸濁液をろ過した。ろ過上清を遠心（８００ｒｐｍ、５ｍｉｎ、２０℃）した後、沈殿した細胞を１０ｖｏｌ％ＦＢＳ含有ＤＭＥＭで懸濁し、褐色脂肪細胞液とした。
(5) Preparation of brown adipocyte fluid After euthanizing ICR mice (Kudo) with diethyl ether, brown adipose tissue was removed from the back. From the obtained brown adipose tissue, adipose tissue, blood vessels, muscles, etc. adhering to the periphery of the brown adipose tissue were removed using tweezers, and then the brown adipose tissue was washed three times in DMEM. Next, the brown fat was immersed in a collagenase solution, and the brown fat was subjected to a shredding treatment in which the brown fat was finely chopped with scissors. The shredded brown fat was incubated in a collagenase solution at 37 ° C. for 1 hour to obtain a cell dispersion. The obtained cell dispersion was filtered through a cell strainer having a pore size of 100 μm, and then subjected to centrifugation (800 rpm, 5 min, 20 ° C.). Then, the precipitated cells were suspended in DMEM to obtain a cell suspension. The resulting cell suspension was then filtered using an autoclave-sterilized 25 μm filter. After centrifuging the filtered supernatant (800 rpm, 5 min, 20 ° C.), the precipitated cells were suspended in DMEM containing 10 vol% FBS to prepare a brown adipocyte fluid.
（６）培地の調製
増殖培地として、１０ｖｏｌ％ＦＢＳ含有ＤＭＥＭを用いた。
(6) Preparation of medium As the growth medium, DMEM containing 10 vol% FBS was used.
分化誘導培地として、増殖培地に２．５μＭ デキサメタゾン、１０μｇ／ｍｌ インスリン及び０．５ｍＭ ＩＢＭＸを含有するものを調製した。 As a differentiation-inducing medium, a growth medium containing 2.5 μM dexamethasone, 10 μg / ml insulin and 0.5 mM IBMX was prepared.
維持培地として、上記インスリン溶液を用いて、増殖培地に１０μｇ／ｍｌ インスリンを含有するものを調製した。 As the maintenance medium, the above insulin solution was used to prepare a growth medium containing 10 μg / ml insulin.
被験物質含有培地は以下のとおりに調製した。すなわち、各被験物質をＤＭＳＯに溶解後、維持培地で希釈して、ＤＭＳＯ終濃度が０．５ｖｏｌ％となるように調製し、フィルター滅菌した。滅菌後、０．５ｖｏｌ％ＤＭＳＯ含有維持培地を用いて所定濃度、すなわち、黒生姜抽出物、ホップ（毬花）、ケツメイシ、メリロートエキス、ショウガ、エラスチン、没食子酸、カフェイン、アルギニン、アラニン、イソマルトオリゴ糖、フラクトオリゴ糖、グルタミン酸及びメチオニンを２０μｇ／ｍｌ又は４０μｇ／ｍｌとなるように、トログリタゾンは１０μＭになるように希釈した。 The test substance-containing medium was prepared as follows. That is, each test substance was dissolved in DMSO, diluted with a maintenance medium, prepared so that the final concentration of DMSO was 0.5 vol%, and sterilized by a filter. After sterilization, use a maintenance medium containing 0.5 vol% DMSO to a predetermined concentration, that is, black ginger extract, hop (barb), ketsumeishi, melilote extract, ginger, elastin, gallic acid, caffeine, arginine, alanine, iso Malto-oligosaccharides, fructo-oligosaccharides, glutamic acid and methionine were diluted to 20 μg / ml or 40 μg / ml, and troglycazone was diluted to 10 μM.
（７）細胞培養
７５ｃｍ２フラスコにコラーゲンコート溶液を５ｍｌ入れ、室温で約１時間静置後、コラーゲンコート溶液を吸引除去し、５ｍｌのＰＢＳで２回洗浄を行うことによって、コラーゲンコートフラスコを得た。
(7) Cell culture A collagen-coated flask was obtained by putting 5 ml of a collagen-coated solution in a 75 cm 2 flask, allowing it to stand at room temperature for about 1 hour, removing the collagen-coated solution by suction, and washing twice with 5 ml of PBS. It was.
褐色脂肪細胞液をコラーゲンコートフラスコに加え、３７℃、５％ＣＯ２インキュベーター内で、褐色脂肪細胞を２４時間培養した。次いで、培養後の褐色脂肪細胞を、増殖培地を用いて１回洗浄した後、新しい増殖培地に交換し、サブコンフルエントになるまで培養を行った。 The brown adipocyte solution was added to a collagen-coated flask, and the brown adipocytes were cultured for 24 hours in a 5% CO 2 incubator at 37 ° C. Then, the brown adipocytes after culturing were washed once with a growth medium, replaced with a new growth medium, and cultured until they became subconfluent.
培養後の褐色脂肪細胞をトリプシン処理に供し浮遊させた。得られた浮遊細胞を、コラーゲンコート（コラーゲンコート溶液 ３５０μＬ／ウェル、ＰＢＳ洗浄 ３５０μＬ／ウェル×２回）した２４ウェルプレートの各ウェルに播種した。 The brown adipocytes after culturing were subjected to trypsin treatment and suspended. The obtained floating cells were seeded in each well of a 24-well plate coated with collagen (collagen coat solution 350 μL / well, PBS wash 350 μL / well × 2 times).
増殖培地を用いてコンフルエントになるまで、褐色脂肪細胞を培養した。各ウェルより培地を除去後、各ウェルに分化誘導培地を５００μｌ添加し、４８時間培養した。 Brown adipocytes were cultured in growth medium until confluent. After removing the medium from each well, 500 μl of the differentiation-inducing medium was added to each well, and the cells were cultured for 48 hours.
分化誘導培地を除去後、２０μｇ／ｍｌ被験物質含有培地の５００μｌを添加し、６日間培養した。培地は１日おきに交換した。黒生姜抽出物と各被験物質とを組み合わせた培地については、それぞれの４０μｇ／ｍｌ被験物質含有培地を２５０μｌずつ添加し、被験物質の最終濃度がそれぞれ２０μｇ／ｍＬとなるようにした。 After removing the differentiation-inducing medium, 500 μl of a 20 μg / ml test substance-containing medium was added, and the cells were cultured for 6 days. The medium was changed every other day. For the medium in which the black ginger extract and each test substance were combined, 250 μl of each 40 μg / ml test substance-containing medium was added so that the final concentration of each test substance was 20 μg / mL.
８日間の培養後、上清を回収し、ＲＮｅａｓｙ Ｍｉｎｉ Ｋｉｔ（キアゲン社）を用いてＲＮＡを回収し、ＱｕａｎｔｉＴｅｃｔ Ｒｅｖｅｒｓｅ Ｔｒａｎｓｃｒｉｐｔｉｏｎ Ｋｉｔ（キアゲン社）を用いてｃＤＮＡを合成した。 After culturing for 8 days, the supernatant was collected, RNA was collected using RNeasy Mini Kit (Qiagen), and cDNA was synthesized using QuantiTect Reverse Transcription Kit (Qiagen).
得られたｃＤＮＡを鋳型として、ＵＣＰ１遺伝子に対するプライマー（キアゲン社）を用いて、Ｒｏｔｏｒ−Ｇｅｎｅ ＳＹＢＲ Ｇｒｅｅｎ ＰＣＲ Ｋｉｔ（キアゲン社）により定量リアルタイムＰＣＲを行い、ＵＣＰ１のｍＲＮＡ発現量を測定した。内在性コントロールとして、ＧＡＰＤＨプライマー（キアゲン社）を用いて、ＧＡＰＤＨのｍＲＮＡ発現量を測定した。 Using the obtained cDNA as a template and using a primer for the UCP1 gene (Kiagen), quantitative real-time PCR was performed by Rotor-Gene SYBR Green PCR Kit (Kiagen) to measure the mRNA expression level of UCP1. As an endogenous control, the mRNA expression level of GAPDH was measured using a GAPDH primer (Qiagen).
（８）評価
ホップ、ケツメイシ、メリロートエキス、ショウガ、エラスチン、没食子酸、カフェイン、アルギニン、アラニン、イソマルトオリゴ糖、フラクトオリゴ糖、グルタミン酸及びメチオニンの各被験物質のそれぞれについて、黒生姜抽出物単独、被験物質単独及び黒生姜抽出物と被験物質との組み合わせを供した場合における、ＵＣＰ１のｍＲＮＡ発現量の測定結果（内在性コントロールに対する相対発現量）を表１に示す。
表１が示すように、ホップ、ケツメイシ、メリロートエキス、ショウガ、エラスチン、没食子酸、カフェイン、アルギニン、アラニン、イソマルトオリゴ糖及びフラクトオリゴ糖を被験物質とした場合は、黒生姜抽出物単独又は被験物質単独よりも、黒生姜抽出物と被験物質とを組み合わせた方が、ＵＣＰ１発現量は大きかった。 As shown in Table 1, when hop, ketsumeishi, melilote extract, ginger, elastin, gallic acid, caffeine, arginine, alanine, isomaltooligosaccharide and fructo-oligosaccharide are used as test substances, black ginger extract alone or test substance The UCP1 expression level was higher in the combination of the black ginger extract and the test substance than in the case of the single substance.
それに対して、驚くべきことに、グルタミン酸及びメチオニンを被験物質とした場合は、黒生姜抽出物単独又は被験物質単独に対して、黒生姜抽出物と被験物質とを組み合わせるとＵＣＰ１発現量は小さくなった。 On the other hand, surprisingly, when glutamic acid and methionine were used as test substances, the UCP1 expression level decreased when the black ginger extract and the test substance were combined with respect to the black ginger extract alone or the test substance alone. It was.
さらに驚くべきことに、ホップ、ケツメイシ、メリロートエキス、エラスチン、没食子酸、カフェイン、アルギニン及びイソマルトオリゴ糖を被験物質とした場合は、黒生姜抽出物単独及び被験物質単独の合計ＵＣＰ１発現量よりも、黒生姜抽出物と被験物質との組み合わせのＵＣＰ１発現量は大きかった。 Even more surprisingly, when hops, ketsumeishi, melilote extract, elastin, thermogenin, caffeine, arginine and isomaltooligosaccharide were used as test substances, the total UCP1 expression level of black ginger extract alone and the test substance alone was higher. The UCP1 expression level of the combination of the black ginger extract and the test substance was high.
以上の結果は、黒生姜抽出物は、ホップ、ケツメイシ、メリロートエキス、ショウガ、エラスチン、没食子酸、カフェイン、アルギニン、アラニン、イソマルトオリゴ糖又はフラクトオリゴ糖と組み合わせることによって、相加的よりもむしろ相乗的にＵＣＰ１のｍＲＮＡ発現量を促進することがわかった。 The above results show that black ginger extract is synergistic rather than additive by combining with hops, ketsumeishi, melilot extract, ginger, elastin, gallic acid, caffeine, arginine, alanine, isomaltooligosaccharides or fructo-oligosaccharides. It was found that it promotes the mRNA expression level of UCP1.
［２．黒生姜抽出物と副素材との組み合わせによる官能試験の影響評価］
被験物質としてイソマルトオリゴ糖、フラクトオリゴ糖、乳果オリゴ糖、アラニン及びセリンを用いて、黒生姜抽出物単独、被験物質単独及び黒生姜抽出物と被験物質とを組み合わせた組成物を供試物として、甘味、苦味、えぐ味などの項目について官能評価を実施した。供試物２ｇを、水１００ｍｌに懸濁して、各被験試料を得た。被験者として、健常な成人９名を無作為に選出した。
[2. Evaluation of the effect of sensory test by combining black ginger extract and secondary material]
Using isomaltooligosaccharide, fructooligosaccharide, milk fruit oligosaccharide, alanine and serine as test substances, black ginger extract alone, test substance alone, and a composition combining black ginger extract and test substance as a test sample. , Sweetness, bitterness, and ginger taste were evaluated. 2 g of the test sample was suspended in 100 ml of water to obtain each test sample. Nine healthy adults were randomly selected as subjects.
これらの被験者９名のそれぞれに対し、各被験試料を経口摂取させ、官能に関する評価を評点法により実施した。評価項目は、「香り」、「味の好み」、「飲み易さ」、「甘さの好み」、「苦さ」、「後味」及び「嗜好性」の７項目とした。 Each of these 9 subjects was orally ingested with each test sample, and the sensory evaluation was performed by the scoring method. The evaluation items were 7 items of "aroma", "taste preference", "easiness to drink", "sweetness preference", "bitterness", "aftertaste" and "preference".
官能評価の各項目について、以下のとおりに、評点をつけた。なお、黒生姜抽出物単独についての各項目の評点を５とした。
香り：悪い １ ← ５ → ９ 良い
味の好み：味が好ましくない １ ← ５ → ９ 味が好ましい
飲み易さ：悪い １ ← ５ → ９ 良い
甘さの好み：甘くない １ ← ５ → ９ 甘い
苦さ：苦い １ ← ５ → ９ 苦くない
後味：悪い １ ← ５ → ９ 良い
嗜好性：嗜好性が低い １ ← ５ → ９ 嗜好性が高い
Each item of sensory evaluation was scored as follows. The score of each item for the black ginger extract alone was set to 5.
Aroma: Bad 1 ← 5 → 9 Good taste preference: Not good taste 1 ← 5 → 9 Good taste Easy to drink: Bad 1 ← 5 → 9 Good taste preference: Not sweet 1 ← 5 → 9 Sweet bitterness S: Bitter 1 ← 5 → 9 Not bitter Aftertaste: Bad 1 ← 5 → 9 Good taste: Low taste 1 ← 5 → 9 High taste
各項目の評点の平均値をとった官能評価の結果について、被験物質別に図１〜図５にそれぞれ示す。 The results of the sensory evaluation obtained by taking the average value of the scores of each item are shown in FIGS. 1 to 5 for each test substance.
図１〜５に示されているとおり、総じて、黒生姜抽出物単独又は被験物質単独よりも、黒生姜抽出物と被験物質とを組み合わせた組成物の方が評価項目が優れていた。これらの結果から、被験物質をイソマルトオリゴ糖、フラクトオリゴ糖、乳果オリゴ糖、アラニン及びセリンとした場合、黒生姜抽出物及び被験物質を含有する組成物は、飲食において嗜好性に優れるものであった。 As shown in FIGS. 1 to 5, the evaluation items of the composition in which the black ginger extract and the test substance were combined were generally superior to those of the black ginger extract alone or the test substance alone. From these results, when the test substance is isomaltooligosaccharide, fructooligosaccharide, milk fruit oligosaccharide, alanine and serine, the composition containing the black ginger extract and the test substance has excellent palatability in eating and drinking. It was.
本発明の組成物は、非経口的及び経口的のいずれの態様においても適用可能な黒生姜及び特定の成分を含むものであり、特にセルライト、肥満やそれらに伴う疾病を被る被験体にとって有用なものであり、このような被験体の健康及び福祉に資するものである。 The compositions of the present invention contain black ginger and certain ingredients that are applicable in both parenteral and oral embodiments and are particularly useful for subjects suffering from cellulite, obesity and associated illnesses. It contributes to the health and welfare of such subjects.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019091315A JP6765090B2 (en) | 2019-05-14 | 2019-05-14 | Black ginger-containing composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019091315A JP6765090B2 (en) | 2019-05-14 | 2019-05-14 | Black ginger-containing composition |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015038887A Division JP6527715B2 (en) | 2015-02-27 | 2015-02-27 | Black ginger containing composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020147913A Division JP2020193230A (en) | 2020-09-02 | 2020-09-02 | Kaempferia parviflora-containing compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019147824A JP2019147824A (en) | 2019-09-05 |
| JP6765090B2 true JP6765090B2 (en) | 2020-10-07 |
Family
ID=67849157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019091315A Active JP6765090B2 (en) | 2019-05-14 | 2019-05-14 | Black ginger-containing composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6765090B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113952314B (en) * | 2021-09-01 | 2023-05-12 | 西安诺众康健生物科技有限责任公司 | Tea polyphenol-gingerol combined particles and preparation method and application thereof |
| CN114304447A (en) * | 2022-01-14 | 2022-04-12 | 北京极暖网络科技有限公司 | Liquid beverage capable of promoting discharge of combustion, resisting fat and oil and producing warm feeling when taken |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0753091B2 (en) * | 1987-04-13 | 1995-06-07 | 昭和産業株式会社 | Health food manufacturing method |
| EP2143443B1 (en) * | 2007-04-03 | 2014-11-19 | Mitsubishi Tanabe Pharma Corporation | A combination of dipeptidyl peptidase iv inhibitor and sweetener for use in the treatment of obesity |
| WO2008143182A1 (en) * | 2007-05-17 | 2008-11-27 | Kaneka Corporation | Composition containing licorice-derived polyphenol |
| JP5121308B2 (en) * | 2007-05-28 | 2013-01-16 | ハウスウェルネスフーズ株式会社 | Composition for preventing, improving or treating metabolic syndrome |
| JP5633028B2 (en) * | 2012-07-10 | 2014-12-03 | 株式会社東洋新薬 | Sympathetic nerve activator |
| JP5569848B2 (en) * | 2012-09-13 | 2014-08-13 | 株式会社東洋新薬 | Composition containing black ginger ingredients |
| US20150296851A1 (en) * | 2012-11-27 | 2015-10-22 | Shanghai Jiao Tong University | Compositions for Balancing Gut Microbiota and the Preparation and the Uses thereof |
| JP5863721B2 (en) * | 2013-07-24 | 2016-02-17 | 丸善製薬株式会社 | Obesity-relieving agent, lipolysis promoter, cyclic AMP-phosphodiesterase activity inhibitor, and rat epididymal fat cell lipolysis promoter |
| JP2016102064A (en) * | 2013-08-14 | 2016-06-02 | 株式会社明治 | Lipid metabolism accelerating agent |
-
2019
- 2019-05-14 JP JP2019091315A patent/JP6765090B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019147824A (en) | 2019-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6688492B2 (en) | Black ginger-containing PPARγ expression promoting composition | |
| JP3768795B2 (en) | Xanthine oxidase inhibitor | |
| JP6765090B2 (en) | Black ginger-containing composition | |
| JP6527715B2 (en) | Black ginger containing composition | |
| KR101964249B1 (en) | Composition for preventing, improving or treating atopic dermatitis comprising mixture of Torilis japonica extract and copper tripeptide-1 as effective component | |
| JP6055667B2 (en) | Collagen production promoter | |
| JP2004345959A (en) | Melanogenesis promoter and melanogenesis-promoting composition | |
| JP6108352B2 (en) | Fatigue improving composition | |
| JP2016188180A (en) | Composition containing specific component | |
| JP6895860B2 (en) | Slimming foods and topical compositions | |
| WO2022169066A1 (en) | Functional collagen composition using aurea helianthus-derived collagen amino acid | |
| JP6541061B2 (en) | Composition for promoting clock gene expression | |
| JP7217550B2 (en) | Composition containing black ginger | |
| JP7090864B2 (en) | Composition | |
| JP5689247B2 (en) | Ceramide production promoter and moisturizer | |
| JP2010180141A (en) | Anti-allergic composition | |
| JP4585227B2 (en) | Slimming kit | |
| JP7222559B2 (en) | Specific ingredient-containing composition | |
| JP2019094357A (en) | Clock gene expression promoting composition | |
| JP2017088616A (en) | Kaempferia parviflora-containing compositions | |
| JP2019180304A (en) | Anti-glycation composition and food product | |
| KR102292114B1 (en) | Composition for Improving Skin Conditions Having Moisturizing, Anti-Inflammatory Caused by Fine Dust and Pore Shrinkage Property Comprising Plant Complex Extracts as Active Ingredient | |
| JP2016056163A (en) | KAEMPFERIA PARVIFLORA-CONTAINING PPARγ EXPRESSION PROMOTING COMPOSITION | |
| JP6753662B2 (en) | Anti-glycation agent | |
| JP6151027B2 (en) | Ceramide production promoter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190603 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200319 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200407 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200605 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200804 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200902 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6765090 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |